FDA Places Partial Clinical Hold on Phase 3 Gotistobart NSCLC Trial
The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
MTX110 May Show Survival Benefits in Recurrent Glioblastoma
Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma
Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.
Financial Toxicity More Prevalent in Adolescents, Young Adults With Cancer
Adolescents and young adults with cancer more commonly experience financial toxicity and unmet social needs.
